

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No. ANG/24-25/BSE-180

Date 14/11/2024

To.

Department of Corporate Services
BSE Limited
P J Tower, Dalal Street
Mumbai-400001

Ref: - BSE Security Code: 540694

Sub - Unaudited financial result (standalone and consolidated) for the quarter & half year ended 30th September, 2024.

Dear Sir/Madam,

The Board of Directors of the Company at its meeting held on today i.e. 14th November, 2024, has inter-alia approved the Unaudited Financial Result (standalone & consolidated) for the quarter & half year ended 30th September, 2024. Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 please find enclosed as follow:


- (1) Unaudited financial result (standalone and consolidated) as per India Accounting Standards for the quarter & half year ended 30th September 2024; and
- (2) Limited review report (standalone and consolidated) by M/s Khurana Sharma & Co., Statutory Auditor of the Company.


The Board meeting was commenced at 05:00 pm and concluded at 05:40 pm.

Kindly take the same on your record.

Yours faithfully

For **ANG Lifesciences India Limited**


Rajesh Gupta
Managing Director




CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Particulars	Standalone Statement of Assets and Liabilities	
	As at 30 September 2024 (Unaudited)	As at 31 March 2024 (Audited)
A. Assets		
1. Non-current assets		
(a) Property, plant and equipment	5,118.52	5,000.52
(b) Right of use assets	290.11	334.06
(c) Financial assets		
i) Investments		
ii) Other financial assets	352.00	352.00
(c) Other non-current assets	19.38	19.51
Total non-current assets	29.02	29.02
	5,809.03	5,735.11
2. Current assets		
(a) Inventories		
(b) Financial assets	3,861.97	3,423.84
i) Trade receivables		
ii) Cash and cash equivalents	6,608.01	6,926.79
iii) Other bank balances	24.30	8.53
v) Other financial assets	360.83	541.39
(c) Other current assets	1,114.25	1,162.18
(d) Current tax assets	3,967.62	3,774.72
Total current assets	41.88	-
Assets held for sale		
Total assets	15,978.86	15,837.45
		170.00
	21,787.89	21,742.56
B. Equity and liabilities		
Equity		
(a) Equity share capital	1,305.83	1,305.83
(b) Other equity	6,026.89	6,401.50
Total equity	7,332.72	7,707.33
Liabilities		
1. Non-current liabilities		
(a) Financial liabilities		
i) Borrowings	565.65	696.95
ii) Lease liabilities	233.27	277.33
ii) Trade payables	0.00	221.86
iii) Other financial liabilities	17.49	17.49
(b) Deferred tax liabilities (net)	79.24	133.85
(c) Provisions	111.79	98.16
Total non-current liabilities	1,007.44	1,445.64
2. Current liabilities		
(a) Financial liabilities		
i) Borrowings	6,325.17	4,879.67
ii) Lease liabilities	85.99	81.82
ii) Trade payables		
-Total outstanding dues of micro enterprises and small enterprises	3,304.38	2,336.10
-Total outstanding dues of creditors other than micro enterprises and small enterprises	2,356.35	3,481.40
iii) Other financial liabilities	317.59	343.00
(b) Other current liabilities	1,032.15	1,031.37
(c) Provisions	11.26	9.89
(d) Current tax liabilities (net)	14.84	426.34
Total current liabilities	13,447.73	12,589.59
Total equity and liabilities	21,787.89	21,742.56



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Statement of standalone unaudited results for the quarter and six months ended 30 September 2024

Particulars	Quarter ended	Quarter ended	Quarter ended	Six months ended	Six months ended	Year ended
	30 September 2024	30 June 2024	30 September 2023	30 September 2024	30 September 2023	31 March 2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I Revenue from operations						
II Other income	3,215.88	1,617.67	2,957.68	4,833.55	8,018.48	13,136.88
III Total revenue (I+II)	36.36	135.84	33.48	172.20	67.80	83.52
IV Expenses	3,252.24	1,753.51	2,991.16	5,005.75	8,086.28	13,220.40
Cost of materials consumed						
Changes in inventories of finished goods and work-in-progress	2,418.36	1,137.29	1,988.62	3,555.65	5,014.66	9,393.41
Employee benefits expense	(241.95)	(51.48)	(20.02)	(293.43)	315.97	(673.68)
Finance costs	378.79	350.49	397.09	729.28	870.80	1,590.44
Depreciation and amortisation expenses	187.24	166.94	195.92	354.18	389.70	1,590.44
Other expenses	161.97	151.07	197.06	313.04	390.69	932.77
Total expenses (IV)	414.62	374.07	460.05	788.69	1,118.22	1,915.20
V Loss before exceptional items and tax (III-IV)	3,319.03	2,128.38	3,218.73	5,447.41	8,100.05	13,933.63
VI Exceptional items	(66.79)	(374.87)	(227.57)	(441.66)	(13.78)	(713.23)
VII Loss before tax (V-VI)	-	-	-	-	-	173.51
Tax expense	(66.79)	(374.87)	(227.57)	(441.66)	(13.78)	(886.74)
(1) Current tax						
(2) Deferred tax			(34.61)	-	47.27	0.13
VIII Total tax expense (1+2)	40.60	(98.34)	12.05	(57.74)	(15.71)	(22.06)
IX Loss for the period (VII-VIII)	40.60	(98.34)	(22.56)	(57.74)	31.56	(21.93)
X Other comprehensive income:	(107.39)	(276.53)	(205.01)	(383.92)	(45.34)	(864.81)
Items that will not be reclassified to profit or (loss)						
Income tax relating to items that will not be reclassified to profit or loss	12.44	-	6.97	12.44	17.78	24.88
	(3.13)	-	(1.75)	(3.13)	(4.47)	(6.26)
XI Total comprehensive loss (IX+X)	(98.08)	(276.53)	(199.80)	(374.61)	(32.04)	(846.19)
XII Paid-up equity share capital (Face value ₹ 10/- per share)						
XIII Other equity	1,305.83	1,305.83	1,305.83	1,305.83	1,305.83	1,305.83
XIV Earnings per equity share (of ₹ 10/- each)						
- Basic and Diluted	(0.75)	(2.12)	(1.53)	(2.87)	(0.25)	6,401.50
						(6.48)

See accompanying notes to the financial results.



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Standalone Cash Flow Statement

(₹ in lacs)

	Six months ended 30 September 2024 (Unaudited)	Six months ended 30 September 2023 (Unaudited)
A. CASH FLOW FROM OPERATING ACTIVITIES		
Loss before tax		
Adjustment for:		
Depreciation and amortization expense	(441.66)	(13.78)
Bad debts written off	313.04	390.69
Provision for expected credit loss	19.81	25.51
Liabilities no longer required, written back	16.20	16.26
Finance cost	118.28	8.50
Interest income	354.18	389.70
Gain on sale of property, plant and equipment	(26.73)	(24.61)
Operating profit before working capital changes	-	(1.34)
Adjustments for movement in:	353.12	790.93
Inventories		
Trade receivables	(438.13)	114.38
Other financial assets	282.78	519.72
Other assets	48.06	24.28
Other financial liabilities	(192.90)	77.04
Provisions	(62.20)	90.48
Trade payables	27.45	16.01
Other liabilities	(496.91)	89.39
Cash generated from operations	0.78	(37.54)
Income taxes paid	(477.95)	1,684.69
Net cash flow generated from operating activities	(453.38)	(1,164.54)
	(931.33)	520.15
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(180.30)	(46.30)
Proceeds from sale of property, plant and equipment	-	5.18
Movement in fixed deposits	180.56	35.58
Interest received	26.73	24.61
Net cash flow used in investing activities	26.99	19.07
C. CASH FLOW FROM FINANCING ACTIVITIES		
Movement in short term borrowings (net)	1,444.06	160.36
Movement in long term borrowings (net)	(129.87)	(11.72)
Interest paid	(337.52)	(370.50)
Payment of lease liabilities	(56.56)	(201.91)
Net cash flow used in financing activities	920.11	(423.77)
Net Increase/(decrease) in cash and cash equivalents	15.77	115.45
Cash and cash equivalents at the beginning of the year	8.53	20.14
Cash and cash equivalents at the end of the year	24.30	135.59
	23.99	10.97
	0.31	124.62
	24.30	135.59

Notes:
Cash and cash equivalents include:
Cash on hand
Balances with banks on current accounts



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Notes:

1. ANG Lifesciences India Limited ('the Company') is a public listed company incorporated in India and is in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of Dry Powder Injection Vials, Liquid Injections Vials, Ampoules, PFS, Hard Gelatin Capsules, Tablets, Soft Gelatin Capsules, Dry Syrups, Liquid Syrups and Suspension, Lotions etc. ANG's products portfolio comprises of major therapeutic categories such as Antibiotics, Antiviral, Antimalarial, Antiulcer, Carbapenem, Corticosteroid, Penicillin, Beta Lactamase Inhibitor etc.
2. The above unaudited standalone and consolidated financial results of ANG Lifesciences India Limited ('the Company' or 'the Holding Company') and its subsidiary, Mansa Print and Publishers Limited (the Holding and the subsidiary together referred to as 'the Group') have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015, as amended and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended) and other accounting principles generally accepted in India.
3. The above unaudited standalone and consolidated financial results for the quarter and half year ended on 30 September 2024 have been reviewed by the Audit Committee of the Company and taken on record by the Board of Directors in their respective meetings held on 14 November 2024. The Statutory Auditors of the Company have conducted "Limited Review" of these results in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and have expressed an unmodified report on the above results.
4. These financial results are available on the website of the Company at www.anglifesciences.com and are also available on the website of Bombay Stock Exchange at www.bseindia.com.
5. Previous period figures have been re-grouped/reclassified wherever necessary, to conform to current period's classification.

For and on behalf of the Board of Directors of
ANG Lifesciences India Limited

(Managing Director)

Place: Amritsar

Date: 14 November 2024

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT




Ref. No.

Date.....

Consolidated Statement of Assets and Liabilities

(₹ in lacs)

Particulars	As at	
	30 September 2024 (Unaudited)	31 March 2024 (Audited)
A. Assets		
1. Non-current assets		
(a) Property, plant and equipment		
(b) Right-of-use assets	5,599.14	5,505.63
(c) Financial assets	290.11	334.06
(i) Investments		
(ii) Other financial assets	2.57	2.57
d) Income tax asset (net)	21.80	21.73
(e) Deferred tax asset (net)	11.52	11.13
(f) Other non-current assets	414.93	445.93
Total non-current assets	29.02	29.02
	6,369.09	6,350.08
2. Current assets		
(a) Inventories		
(b) Financial assets	5,311.85	4,776.59
(i) Trade receivables		
(ii) Cash and cash equivalents	6,942.23	7,327.75
iii) Other bank balances	34.85	31.85
iv) Other financial assets	361.11	541.67
(c) Other current assets	1,104.16	1,158.28
(d) Current tax assets	3,671.84	3,495.00
Total current assets	41.88	-
Assest held for sale	17,467.92	17,331.15
Total assets	392.47	562.47
	24,229.48	24,243.70
B. Equity and liabilities		
Equity		
(a) Equity share capital		
(b) Other equity	1,305.83	1,305.83
Total equity	5,814.46	6,321.91
	7,120.29	7,627.74
Liabilities		
1. Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings		
(ii) Lease liabilities	1,185.18	1,394.92
(iii) Trade payables	233.27	277.33
(iv) Other financial liabilities	-	221.86
(b) Deferred tax liabilities (net)	17.49	17.49
(c) Provisions	79.24	133.35
Total non-current liabilities	130.42	114.35
	1,645.60	2,159.30
2. Current liabilities		
(a) Financial liabilities		
(i) Borrowings		
(ii) Lease liabilities	7,043.63	5,529.58
(iii) Trade payables	85.99	81.82
-Total outstanding dues of micro enterprises and small enterprises		
-Total outstanding dues of creditors other than micro enterprises and small enterprises	4,008.85	2,869.37
(iv) Other financial liabilities	2,528.79	3,748.49
(b) Other current liabilities	377.02	402.50
(c) Provisions	1,390.90	1,386.66
(d) Current tax liabilities (net)	13.57	11.91
Total current liabilities	14.84	426.34
Total equity and liabilities	15,463.59	14,456.66
	24,229.48	24,243.70



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT




Ref. No.

Date.....

Statement of consolidated unaudited results for the quarter and six months ended 30 September 2024

Particulars	Quarter ended 30 September 2024	Quarter ended 30 June 2024	Quarter ended 30 September 2023	Six months ended 30 September 2024	Six months ended 30 September 2023	Year ended 31 March 2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I Revenue from operations						
II Other income	3,288.47	1,841.00	3,326.19	5,129.47	8,972.44	14,610.97
III Total revenue (I+II)	3,323.34	1,969.48	3,348.53	5,292.82	9,026.42	14,680.79
IV Expenses						
Cost of materials consumed						
Changes in inventories of finished goods and work-in-progress	2,413.04	1,224.27	2,201.40	3,637.31	5,615.28	10,278.66
Employee benefits expense	(267.66)	(57.37)	(49.46)	(325.03)	232.27	(767.38)
Finance costs	457.64	426.41	494.73	884.05	1,071.21	1,935.22
Depreciation and amortisation expenses	218.31	208.34	228.99	426.65	460.40	1,095.73
Other expenses	174.22	163.32	222.26	337.54	441.07	837.14
Total expenses (IV)	456.62	418.65	513.70	875.27	1,233.13	2,199.28
V Loss before exceptional items and tax (III-IV)	3,452.17	2,383.62	3,611.61	5,835.79	9,053.36	15,578.65
VI Exceptional items	(128.83)	(414.14)	(263.09)	(542.97)	(26.94)	(897.86)
VII Loss before tax (V-VI)	(128.83)	(414.14)	(263.09)	(542.97)	(26.94)	(173.51)
Tax expense						
(1) Current tax			(34.61)	-	47.27	0.13
(2) Deferred tax	80.09	(106.84)	3.26	(26.75)	(17.69)	(57.19)
VIII Total tax expense (1+2)	80.09	(106.84)	(31.35)	(26.75)	29.58	(57.05)
IX Loss for the period (VII-VIII)	(208.92)	(307.30)	(231.73)	(516.22)	(56.52)	(1,014.30)
X Other comprehensive income:						
Items that will not be reclassified to profit or (loss)						
Income tax relating to items that will not be reclassified to profit or loss	12.44	-	5.31	12.44	17.27	27.59
	(3.13)	-	(1.34)	(3.13)	(4.35)	(6.94)
XI Total comprehensive income (IX+X)	(199.61)	(307.30)	(227.76)	(506.91)	(43.60)	(993.65)
XII Paid-up equity share capital (Face value ₹ 10/- per share)						
XIII Other equity	1,305.83	1,305.83	1,305.83	1,305.83	1,305.83	1,305.83
XIV Earnings per equity share (of ₹ 10/- each)						
a) Basic	(1.53)	(2.35)	(1.74)	(3.88)	(0.33)	(7.61)
b) Diluted	(1.53)	(2.35)	(1.74)	(3.88)	(0.33)	(7.61)

* See accompanying notes to the financial results.



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Consolidated Cash Flow Statement

(₹ in lacs)

	Six months ended 30 September 2024 (Unaudited)	Six months ended 30 September 2023 (Unaudited)
A. CASH FLOW FROM OPERATING ACTIVITIES		
Loss before tax		
Adjustment for:	(542.97)	(26.94)
Depreciation and amortization expense	337.54	441.07
Bad debts written off	19.81	25.51
Provision for expected credit loss	16.20	16.26
Finance cost	426.65	460.40
Interest income	(10.29)	(16.97)
Rent income	-	(0.96)
Gain on sale of fixed assets	-	(1.34)
Liabilities no longer required, written back	(118.28)	(8.50)
Operating profit before working capital changes	128.66	888.53
Adjustments for movement in:		
Inventories		(107.09)
Trade receivables	(535.27)	616.83
Other financial assets	349.51	101.64
Other assets	54.05	(0.75)
Other financial liabilities	(176.83)	120.46
Provisions	(66.80)	18.44
Trade payable	30.17	248.36
Other liabilities	(183.79)	(22.99)
Cash generated from operations	4.24	1,863.43
Income taxes paid	(396.06)	(1,164.76)
Net cash flow generated from operating activities	(849.83)	698.67
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(180.30)	(46.40)
Proceeds from sale of property, plant and equipment	-	5.18
Movement in fixed deposits	180.56	35.59
Interest received	10.29	16.97
Rent received	-	0.96
Net cash flow used in investing activities	10.55	12.30
C. CASH FLOW FROM FINANCING ACTIVITIES		
Movement in long term borrowings (net)	(144.41)	152.78
Movement in short term borrowings (net)	1,448.72	(109.53)
Interest paid	(405.47)	(441.20)
Payment of lease liabilities	(56.56)	(201.91)
Net cash flow used in financing activities	842.28	(599.86)
Net Increase/(decrease) in cash and cash equivalents	3.00	111.11
Cash and cash equivalents at the beginning of the year	31.85	32.42
Cash and cash equivalents at the end of the year	34.85	143.53
	34.29	17.60
	0.56	125.93
	34.85	143.53



Notes:
Cash and cash equivalents include:
Cash on hand
Balances with banks on current accounts

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT




Ref. No.

Date.....

As per Ind-AS 108, Operating Segments have been defined and presented based on the regular review by the Company's Chief Operating Decision Maker to assess the performance of each segment and to make decision about allocation of resources. The accounting principles used in the preparation of the consolidated unaudited financial results are consistently applied to record revenue and expenditure in individual segments. Accordingly, the consolidated unaudited segment wise revenue, results, assets, and liabilities is as follows :

S.No.	Particulars	Quarter ended			Six months ended		Year ended
		30 September 2024	30 June 2024	30 September 2023	30 September 2024	30 September 2023	31 March 2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Segment revenue						
	a) Pharmaceuticals	3,215.88	1,617.67	2,957.68	4,833.55	8,018.48	13,136.88
	b) Printing and packagings	202.68	301.91	456.79	504.59	1,136.18	1,830.15
	Total	3,418.56	1,919.58	3,414.47	5,338.14	9,154.66	14,967.03
	Less: Inter segment revenue	130.09	78.58	88.28	208.67	182.22	356.06
	Revenue from operations	3,288.47	1,841.00	3,326.19	5,129.47	8,972.44	14,610.97
2	Segment results (profit before tax and finance cost from each segment)						
	a) Pharmaceuticals	120.46	(207.94)	(31.66)	(87.48)	376.03	219.50
	b) Printing and packagings	(15.43)	10.28	10.79	(5.15)	74.48	(4.88)
	Total	105.03	(197.66)	(20.87)	(92.63)	450.50	214.62
	Less: Finance costs	233.86	216.48	242.22	450.34	477.44	1,112.49
	Loss before tax	(128.83)	(414.14)	(263.09)	(542.97)	(26.94)	(897.86)
	Particulars				As at 30 September 2024	As at 30 September 2023	As at 31 March 2024 (Audited)
3	Segment Assets						
	a) Pharmaceuticals				21,787.89	23,344.09	20,856.95
	b) Printing and packagings				3,270.13	3,589.59	3,390.66
	Total Segment assets				25,058.02	26,933.68	24,247.61
4	Segment liabilities						
	a) Pharmaceuticals				14,455.17	15,824.86	14,035.25
	b) Printing and packagings				3,132.56	2,531.15	2,934.65
	Total Segment liabilities				17,587.73	18,356.01	16,969.89



KHURANA SHARMA & COMPANY

CHARTERED ACCOUNTANTS

H.No. 1299, SECTOR 15-B, CHANDIGARH

PHONE : 9988070254, 9878029920

Independent Auditor's Review Report on Unaudited Standalone Financial Results of Company for the Quarter ended 30th September, 2024 and year to date from 01st April 2024 to 30th September, 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

To the Board of Directors of ANG Lifesciences India Limited

1. We have reviewed the accompanying statement of Unaudited Standalone financial results ('the Statement') of ANG Lifesciences India Limited (the Company') for the quarter ended 30 September 2024 and year to date from 01st April 2024 to 30th September, 2024 ('the statement') attached herewith being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down' in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations, Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in Scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not



disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s Khurana Sharma & Co.

Chartered Accountants



CA Vibhor Khurana

FRN: 010920N

M. No. 568524

UDIN: 24568524BKAVGR6169

Place: Chandigarh

Date: 14.11.2024

KHURANA SHARMA & COMPANY

CHARTERED ACCOUNTANTS

H.No. 1299, SECTOR 15-B, CHANDIGARH

PHONE : 9988070254, 9878029920

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results of Company for the Quarter ended 30th September, 2024 and year to date from 01st April 2024 to 30th September, 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

To the Board of Directors of ANG Lifesciences India Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated financial results ('the statement') of ANG Lifesciences India Limited ('the Holding Company') and its Wholly owned Subsidiary (the Holding Company and its subsidiary together referred to as 'the Group') for the quarter ended 30 September 2024 and the consolidated year to date results for the period 1st April 2024 to 30th September 2024, being submitted by the Holding Company pursuant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the presentation Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations, Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India, A review Of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD 1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.

5. The statement includes the result of the following entities:
Mansa Print & Publishers Ltd (Wholly Owned Subsidiary Company)



6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s Khurana Sharma & Co.
Chartered Accountants



CA Vibhor Khurana

FRN: 010920N

M. No. 568524

UDIN: 24568524BKAVMS3635

Place: Chandigarh

Date: 14.11.2024